abatacept   

GtoPdb Ligand ID: 6891

Synonyms: BMS-188667 | CTLA4-IgG4m | Orencia® | RG-1046 | RG-2077
abatacept is an approved drug (FDA (2005), EMA (2005))
Compound class: Antibody
Comment: Abatacept is a recombinant protein fusing the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1) [3]. In essence, abatacept is a CTLA-4 mimetic, that enhances CTLA-4's inhibitory signal to T cells, thereby down-modulating T cell mediated inflammation.
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: abatacept

Immunopharmacology Comments
Abatacept is a selective T cell costimulation modulator used in inflammatory autoimmune diseases, that promotes the coinhibitory activity of the immune checkpoint CTLA-4-CD86/CD80 on T cell activation.
Immunopharmacology Disease
Disease X-Refs Comment References
Psoriatic arthritis Disease Ontology: DOID:9008
Approved drug for PsA.
Rheumatoid arthritis Disease Ontology: DOID:7148
OMIM: 180300
Approved drug for RA.
Juvenile idiopathic arthritis- systemic OMIM: 604302
Approved drug for JIA.